Phone interview measuring health-related quality of life variables
OtherA phone interview will be conducted by a dedicated nurse who will be blinded to the exposed/non-exposed status of the patient.
NCT Number: NCT03216577
Purpura fulminans (PF) is a rare life-threatening infectious disease characterized by the association of a sudden and extensive purpura together with acute circulatory failure. The mortality of PF has been reported to be as high as 50% in previous adult series. Additionally, patients surviving to the early phase of PF are exposed to a high risk of limb amputation. The hOPeFUL study aims at assessing the short and long term outcomes of adult patients admitted in the intensive care unit for a purpura fulminans.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Aulnay sous Bois Hospital, Aulnay-sous-Bois, France
Purpura fulminans (PF) is a rare life-threatening infectious disease characterized by the association of a sudden and extensive purpura together with acute circulatory failure. Neisseria meningitidis and Streptococcus pneumoniae are the most frequently involved microorganisms but other species (e.g., Staphylococcus aureus, Streptococcus pyogenes, Haemophilus influenzae…) have also been reported. Despite prompt antibiotics administration and intensive care management, the mortality of PF has been reported to be as high as 50% in previous adult series. Additionally, patients surviving to the early phase of PF are exposed to a high risk of serious sequelae related to extensive skin necrosis and acral symmetrical gangrene, which typically requires limb amputations, a potential source of severe handicap in these previously young and healthy patients. Although the clinical features and outcomes of PF have been well studied in the pediatric setting, the amount of available data for adult PF are scarce, often outdated and mainly limited to patients with meningococcal infections. The current study aims at assessing the short and long-term outcomes of adult patients admitted in the intensive care unit for a purpura fulminans. A large multicenter retrospective cohort will be built in order to assess hospital outcomes (i.e., mortality and amputations). Long-term outcomes, including health-related quality variables, will be prospectively assessed among survivors and compared to septic controls (i.e., patients having septic shock non-related to purpura fulminans).
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
A phone interview will be conducted by a dedicated nurse who will be blinded to the exposed/non-exposed status of the patient.
Time frame: day 60
factors associated with hospital mortality (and rate of amputation in the hospital) will be identified using a polytomous logistic regression model
Time frame: day 60
factors associated with rate of amputation in the hospital (and hospital mortality) will be identified using a polytomous logistic regression model
Time frame: Within 6 years of hospital discharge
This variable will be compared between patients with purpura fulminans and patients with septic shock non-related to purpura fulminans
Time frame: Within 6 years of hospital discharge
This variable will be compared between patients with purpura fulminans and patients with septic shock non-related to purpura fulminans
Time frame: Within 6 years of hospital discharge
This variable will be compared between patients with purpura fulminans and patients with septic shock non-related to purpura fulminans
Time frame: Within 6 years of hospital discharge
This variable will be compared between patients with purpura fulminans and patients with septic shock non-related to purpura fulminans
Time frame: Within 6 years of hospital discharge
This variable will be compared between patients with purpura fulminans and patients with septic shock non-related to purpura fulminans
Time frame: Within 6 years of hospital discharge
This variable will be compared between patients with purpura fulminans who were and those who were not amputated
Time frame: Within 6 years of hospital discharge
This variable will be compared between patients with purpura fulminans who were and those who were not amputated
Henri Mondor University Hospital
Other
Short and Long-term Outcomes of Purpura Fulminans in Adults
Acronym: hOPeFUL
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02238795
Blood Coagulation Disorders, Hematologic Diseases
Jena, Germany
View Trial DetailsNCT05094687
Bacterial Infections and Mycoses, Blood Coagulation Disorders
Karachi, Sindh, Pakistan
View Trial DetailsNCT04070612
Anemia, Anemia, Hemolytic
View Trial DetailsNCT04070599
Autoimmune Diseases, Autoimmune Thrombocytopenia
Bordeaux, France
View Trial Details